Log in

Login to your account

Username *
Password *
Remember Me

Multi Radiance Medical Logo

Call or Contact us today for more information: 1.440.542.0761 Refer a Friend
Sinusitis

The clinico-immunological assessment of the efficacy of magnetic-laser therapy in patients with chronic maxillary sinusitis

Nikolaev MP, Prozorovskaia KN, Skriabin AS, Popov VV.
Vestn Otorinolaringol. 1991 May-Jun;(3):60-3.

Magneto-laser therapy (80 Hz, 0.01 mW/cm2, 12 min) consisting of 10 sessions was performed in patients with maxillary sinusitis (MS). Therapeutic action on the sinus mucosa was conducted through the sinus anterior wall. The magneto-optic attachment coupled with semiconductor laser in the Uzor apparatus was tightly pressed to the facial skin in the sinus projection area. Positive clinical responses associated with stimulation of neutrophil phagocytic activity and with a rise in the portion of rosette-forming neutrophils and Ig A were achieved in 90% of the patients with catarrhal MS and in 83% of those with purulent MS. A 1.5-2-year follow-up registered the effect persistence in 80% and 69% of them, respectively. Compared to standard methods (microwave therapy), magneto-laser treatment was superior both in short-term and long-term effects obtained in purulent MS. The method can be applied in mono- and polytherapy.

Clinical effectiveness of magnetolaser therapy of vasomotor rhinitis

Mamedov AF.

Magnet-laser therapy was used to treat vasomotor rhinitis in 90 patients. A constant magnet of 50 mT was applied to the exterior of the nose, and an infrared laser beam was applied via a light-guide to the reflexogenic zones of concha inferior. The radiation power density was 5 mW/cm2. The magnetic exposure time was 6-10 min and the laser exposure time was 3-5 min for each half of the nose. The therapeutic course was 8-12 sessions. The therapeutic results depended on the type of vasomotor rhinitis, clinical disorders, and duration of the disease. Good results were seen in 84 (93.3%) patients out of 90 cases. Stable remission was recorded in 61.1% patients, significant improvement of clinical manifestations of vasomotor rhinitis was observed in 32.2% cases. Best results were reported in patients with autonomic forms of vasomotor rhinitis who suffered from short-term disease and vasodilation disorders.

Request a Demo
Name (*)

Invalid Input
Email (*)

Invalid Input
Phone

Invalid Input



Upcoming Events

No events

Newsletter

Subscribe to our newsletter below and keep up with our latest news and events

This website contains information that has not been reviewed or approved by the FDA. Some of the claims and representations of the products contained on this site are cleared by regional regulatory bodies such as CE and Health Canada and may differ from those that are FDA 510K cleared.
What does this mean?